Truvestments Capital’s Boston Scientific BSX Stock Holding History

Truvestments Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.6K	Sell	1,046 -217	-17%	-$11.8K	0.01%	554
2026 Q1	$79.2K	Hold	1,263	–	–	0.01%	428
2025 Q4	$120K	Sell	1,263 -302	-19%	-$29.6K	0.02%	314
2025 Q3	$153K	Buy	1,565 +217	+16%	+$22.5K	0.03%	302
2025 Q2	$145K	Sell	1,348 -174	-11%	-$17.6K	0.03%	260
2025 Q1	$154K	Buy	1,522 +942	+162%	+$94.9K	0.03%	257
2024 Q4	$51.8K	Hold	580	–	–	0.01%	364
2024 Q3	$48.6K	Buy	+580	New	+$45.7K	0.01%	362
2021 Q2	–	Sell	-1,694	Closed	-$65K	–	631
2021 Q1	$65K	Sell	1,694 -51	-3%	-$1.93K	0.04%	256
2020 Q4	$63K	Buy	1,745 +751	+76%	+$27.1K	0.04%	231
2020 Q3	$38K	Sell	994 -48	-5%	-$1.85K	0.03%	195
2020 Q2	$35K	Buy	1,042 +344	+49%	+$12.4K	0.04%	244
2020 Q1	$22K	Buy	+698	New	+$27.3K	0.03%	253
2019 Q4	–	Sell	-1,998	Closed	-$81K	–	206
2019 Q3	$81K	Hold	1,998	–	–	0.05%	192
2019 Q2	$86K	Hold	1,998	–	–	0.06%	198
2019 Q1	$77K	Buy	+1,998	New	+$76.3K	0.06%	185
2018 Q3	$77K	Buy	+1,998	New	+$69.8K	0.04%	298

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Truvestments Capital's BSX Position: Q2 2026 in Review

Truvestments Capital reduced its Boston Scientific (BSX) stake by 17% in Q2 2026, selling an estimated $11.8K and leaving 1,046 shares worth $44.6K. The position accounts for 0.01% of the portfolio, ranked #554.

Truvestments Capital first reported a position in BSX in Q3 2018 and has held it in 17 quarters since. The position peaked at $154K in Q1 2025. 1,487 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Truvestments Capital held 1,046 shares of Boston Scientific worth $44.6K as of Q2 2026.
Truvestments Capital sold 217 Boston Scientific shares in Q2 2026, an estimated $11.8K.
Boston Scientific made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #554 holding.
Truvestments Capital first reported a position in Boston Scientific in Q3 2018 and has held it in 17 quarters since.
Truvestments Capital's Boston Scientific position peaked at $154K in Q1 2025.
1,487 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.